Tidal Investments LLC boosted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 59.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 104,478 shares of the company's stock after purchasing an additional 38,887 shares during the period. Tidal Investments LLC owned approximately 0.05% of Cellebrite DI worth $1,759,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of CLBT. FMR LLC grew its position in shares of Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company's stock valued at $94,586,000 after acquiring an additional 3,239,307 shares during the period. Principal Financial Group Inc. bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $23,402,000. Pembroke Management LTD grew its position in shares of Cellebrite DI by 104.9% during the 2nd quarter. Pembroke Management LTD now owns 1,535,726 shares of the company's stock valued at $18,352,000 after acquiring an additional 786,310 shares during the period. Summit Partners Public Asset Management LLC bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $9,274,000. Finally, Meitav Investment House Ltd. grew its position in shares of Cellebrite DI by 29.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company's stock valued at $34,797,000 after acquiring an additional 473,293 shares during the period. Institutional investors own 45.88% of the company's stock.
CLBT has been the subject of a number of recent research reports. TD Cowen boosted their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. Craig Hallum lifted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Monday. Finally, Needham & Company LLC lifted their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $20.57.
Read Our Latest Stock Analysis on Cellebrite DI
Shares of CLBT stock opened at $20.23 on Wednesday. The stock has a market cap of $4.17 billion, a P/E ratio of -13.05, a PEG ratio of 2.71 and a beta of 1.51. Cellebrite DI Ltd. has a 52 week low of $7.91 and a 52 week high of $21.72. The company's fifty day simple moving average is $19.02 and its two-hundred day simple moving average is $15.95.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. The business had revenue of $106.90 million for the quarter, compared to analysts' expectations of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business's quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.09 EPS. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.32 EPS for the current fiscal year.
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.